1203662-37-6

Basic information

• Product Name: 4-BroMo-1H-indazol-5-carboxylic acid tert-butyl ester
• Synonyms: 4-BroMo-1H-indazol-5-carboxylic acid tert-butyl ester;1H-Indazole-5-carboxylic acid, 4-broMo-, 1,1-diMethylethyl ester;4-Bromo-5-(tert-butoxycarbonyl)-1H-indazole;tert-Butyl 4-bromo-1H-indazole-5-carboxylate;3,2-DIOXABOROLAN-2-YL)THIOPHEN-2-YL);4-Bromo-1H-indazole-5-carboxylic acid tert-butyl ester
• CAS NO: 1203662-37-6
• Molecular Formula: C12H13BrN2O2
• Molecular Weight: 297.14782
• EINECS: -0
• Mol File: 1203662-37-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 404.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.495±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.63±0.40(Predicted)
• CAS DataBase Reference: 4-BroMo-1H-indazol-5-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-1H-indazol-5-carboxylic acid tert-butyl ester(1203662-37-6)
• EPA Substance Registry System: 4-BroMo-1H-indazol-5-carboxylic acid tert-butyl ester(1203662-37-6)

Safety Data

• Hazardous Substances Data: 1203662-37-6(Hazardous Substances Data)

Usage

Description

4-BroMo-1H-indazol-5-carboxylic acid tert-butyl ester is a chemical compound that can be synthesized and used as a pharmaceutical agent. It is characterized by its indazole core structure, with a bromine atom at the 4-position and a carboxylic acid group at the 5-position, which is esterified with a tert-butyl group. 4-BroMo-1H-indazol-5-carboxylic acid tert-butyl ester has potential applications in the development of therapeutic agents targeting specific biological pathways.

Uses

Used in Pharmaceutical Industry:
4-BroMo-1H-indazol-5-carboxylic acid tert-butyl ester is used as an inhibitor of MNK1 and MNK2 for treating MNK-mediated diseases. MNK1 and MNK2 are kinases involved in the regulation of eukaryotic initiation factor 4E (eIF4E), which plays a crucial role in the translation process of cellular proteins. Inhibition of MNK1 and MNK2 can help modulate the activity of eIF4E, potentially leading to the treatment of diseases where abnormal protein translation is implicated, such as cancer and inflammatory disorders.

Upstream product

• 1203662-35-4 2-bromo-4-fluoro-3-formylbenzoic acid tert-butyl ester 
• 951884-50-7 2-bromo-4-fluorobenzoic acid tert-butyl ester 
• 1006-41-3 2-bromo-4-fluorobenzoic acid 

Downstream Products

• 1203663-13-1 4-[(4-bromo-2-fluorophenyl)amino]-1H-indazole-5-carboxylic acid (2-hydroxyethoxy)amide 
• 1203663-23-3 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid cyclopropylmethoxyamide 
• 1203663-21-1 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid ethoxyamide 
• 1374328-76-3 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid (3-hydroxypropyl)amide 
• 1203663-26-6 [4-[(2-fluoro-4-iodophenyl)amino]-1H-indazol-5-yl]-(3-hydroxyazetidin-1-yl)methanone 
• 1203663-02-8 G-894 
• 1203662-73-0 4-(2-fluoro-4-iodophenylamino)-indazole-1,5-dicarboxylic acid di-tert-butyl ester 
• 1203662-69-4 4-[(4-bromo-2-fluorophenyl)amino]-1H-indazole-1,5-dicarboxylic acid di-tert-butylester 
• 1203663-04-0 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid (2-vinyloxyethoxy)amide 
• 1203663-14-2 4-(4-bromo-2-fluorophenylamino)-1H-indazole-5-carboxylic acid (2-vinyloxyethoxy)amide 
• 1203663-12-0 4-(2-fluoro-4-iodophenylamino)-1H-indazole-5-carboxylic acid ((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)amide 
• 1203662-67-2 4-(2-fluoro-4-trimethylsilanylphenylamino)indazole-1,5-dicarboxylic acid di-tert-butyl ester 
• 1203662-71-8 4-[(2-fluoro-4-iodophenyl)amino]-1H-indazole-5-carboxylic acid 
• 1203662-65-0 4-[(4-bromo-2-fluorophenyl)amino]-1H-indazole-5-carboxylic acid 

Relevant articles and documents

BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, Y1, Y2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS

The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.